No Data
No Data
Express News | TFF Pharmaceuticals Engages Outcome Capital as a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
TFF Pharmaceuticals Announced A Regulatory Update On Its TFF TAC Clinical Program Following Its Recent Interaction With The FDA, Company To Provide More Detailed Regulatory Update In 3Q 2024
In April 2024, the Company submitted a briefing book to the FDA to help guide the next steps in the clinical development pathway for TFF TAC. Following its review of the briefing book, the FDA concurr
Express News | TFF Pharmaceuticals: Based on FDA Feedback, Does Not Expect Change to Timelines or Estimated Costs Associated With Clinical Advancement of TFF Tac
Express News | TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF Tac) Clinical Program for the Prevention of Lung Transplant Rejection
Express News | TFF Pharmaceuticals Inc - Mcm Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated in Vitro and Ex Vivo Models
Express News | TFF Pharmaceuticals Inc - Co and Leidos to Advance Next-Generation Biodefense Countermeasures Under Darpa PPB Program Into Preclinical Testing